Cargando…
Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
This study investigated the applicability of personalized peptide vaccination (PPV) for patients with metastatic upper tract urothelial cancer (mUTUC) after failure of platinum‐based chemotherapy. In this single arm, open‐label, phase II clinical trial, patients with mUTUC received PPV at a single i...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715265/ https://www.ncbi.nlm.nih.gov/pubmed/28940789 http://dx.doi.org/10.1111/cas.13404 |
_version_ | 1783283731253952512 |
---|---|
author | Suekane, Shigetaka Ueda, Kousuke Nishihara, Kiyoaki Sasada, Tetsuro Yamashita, Takuto Koga, Noriko Yutani, Shigeru Shichijo, Shigeki Itoh, Kyogo Igawa, Tsukasa Noguchi, Masanori |
author_facet | Suekane, Shigetaka Ueda, Kousuke Nishihara, Kiyoaki Sasada, Tetsuro Yamashita, Takuto Koga, Noriko Yutani, Shigeru Shichijo, Shigeki Itoh, Kyogo Igawa, Tsukasa Noguchi, Masanori |
author_sort | Suekane, Shigetaka |
collection | PubMed |
description | This study investigated the applicability of personalized peptide vaccination (PPV) for patients with metastatic upper tract urothelial cancer (mUTUC) after failure of platinum‐based chemotherapy. In this single arm, open‐label, phase II clinical trial, patients with mUTUC received PPV at a single institution. Personalized peptide vaccination treatment used a maximum of four peptides chosen from 27 candidate peptides according to human leukocyte antigen types and peptide‐reactive IgG titers, for six s.c. injections weekly as one cycle. The safety of PPV, as well as its influence on host immunity and effect on overall survival were assessed. Forty‐eight patients were enrolled in this study. Personalized peptide vaccinations were well tolerated without severe adverse events. Median survival time was 7.3 months (95% confidence interval [CI], 5.3–13.1) with 13.0 months for patients receiving combined salvage chemotherapy (95% CI, 5.7–17.5) and 4.5 months for patients receiving PPV alone (95% CI, 1.7–10.1) (P = 0.080). Patients with positive CTL responses showed a significantly longer survival than patients with negative CTL responses (hazard ratio, 0.37; 95% CI, 0.16–0.85; P = 0.019). Multivariate Cox regression analysis showed that lower numbers of Bellmunt risk factors and lower levels of B‐cell activating factor were significantly associated with favorable overall survival for patients under PPV treatment. This study indicated that PPV for patients with mUTUC after failure of platinum‐based chemotherapy induced substantial peptide‐specific CTL responses without severe adverse events and has the potential to prolong survival when combined with salvage chemotherapy. UMIN Clinical Trials Registry ID: 000001854. |
format | Online Article Text |
id | pubmed-5715265 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57152652017-12-08 Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma Suekane, Shigetaka Ueda, Kousuke Nishihara, Kiyoaki Sasada, Tetsuro Yamashita, Takuto Koga, Noriko Yutani, Shigeru Shichijo, Shigeki Itoh, Kyogo Igawa, Tsukasa Noguchi, Masanori Cancer Sci Original Articles This study investigated the applicability of personalized peptide vaccination (PPV) for patients with metastatic upper tract urothelial cancer (mUTUC) after failure of platinum‐based chemotherapy. In this single arm, open‐label, phase II clinical trial, patients with mUTUC received PPV at a single institution. Personalized peptide vaccination treatment used a maximum of four peptides chosen from 27 candidate peptides according to human leukocyte antigen types and peptide‐reactive IgG titers, for six s.c. injections weekly as one cycle. The safety of PPV, as well as its influence on host immunity and effect on overall survival were assessed. Forty‐eight patients were enrolled in this study. Personalized peptide vaccinations were well tolerated without severe adverse events. Median survival time was 7.3 months (95% confidence interval [CI], 5.3–13.1) with 13.0 months for patients receiving combined salvage chemotherapy (95% CI, 5.7–17.5) and 4.5 months for patients receiving PPV alone (95% CI, 1.7–10.1) (P = 0.080). Patients with positive CTL responses showed a significantly longer survival than patients with negative CTL responses (hazard ratio, 0.37; 95% CI, 0.16–0.85; P = 0.019). Multivariate Cox regression analysis showed that lower numbers of Bellmunt risk factors and lower levels of B‐cell activating factor were significantly associated with favorable overall survival for patients under PPV treatment. This study indicated that PPV for patients with mUTUC after failure of platinum‐based chemotherapy induced substantial peptide‐specific CTL responses without severe adverse events and has the potential to prolong survival when combined with salvage chemotherapy. UMIN Clinical Trials Registry ID: 000001854. John Wiley and Sons Inc. 2017-10-12 2017-12 /pmc/articles/PMC5715265/ /pubmed/28940789 http://dx.doi.org/10.1111/cas.13404 Text en © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Suekane, Shigetaka Ueda, Kousuke Nishihara, Kiyoaki Sasada, Tetsuro Yamashita, Takuto Koga, Noriko Yutani, Shigeru Shichijo, Shigeki Itoh, Kyogo Igawa, Tsukasa Noguchi, Masanori Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma |
title | Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma |
title_full | Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma |
title_fullStr | Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma |
title_full_unstemmed | Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma |
title_short | Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma |
title_sort | personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715265/ https://www.ncbi.nlm.nih.gov/pubmed/28940789 http://dx.doi.org/10.1111/cas.13404 |
work_keys_str_mv | AT suekaneshigetaka personalizedpeptidevaccinationassecondlinetreatmentformetastaticuppertracturothelialcarcinoma AT uedakousuke personalizedpeptidevaccinationassecondlinetreatmentformetastaticuppertracturothelialcarcinoma AT nishiharakiyoaki personalizedpeptidevaccinationassecondlinetreatmentformetastaticuppertracturothelialcarcinoma AT sasadatetsuro personalizedpeptidevaccinationassecondlinetreatmentformetastaticuppertracturothelialcarcinoma AT yamashitatakuto personalizedpeptidevaccinationassecondlinetreatmentformetastaticuppertracturothelialcarcinoma AT koganoriko personalizedpeptidevaccinationassecondlinetreatmentformetastaticuppertracturothelialcarcinoma AT yutanishigeru personalizedpeptidevaccinationassecondlinetreatmentformetastaticuppertracturothelialcarcinoma AT shichijoshigeki personalizedpeptidevaccinationassecondlinetreatmentformetastaticuppertracturothelialcarcinoma AT itohkyogo personalizedpeptidevaccinationassecondlinetreatmentformetastaticuppertracturothelialcarcinoma AT igawatsukasa personalizedpeptidevaccinationassecondlinetreatmentformetastaticuppertracturothelialcarcinoma AT noguchimasanori personalizedpeptidevaccinationassecondlinetreatmentformetastaticuppertracturothelialcarcinoma |